Healthcare AI Targets Trial Enrollment

GenomOncology (GO) is a precision medicine company that uses AI to improve cancer care by converting complex data into actionable insights. Their platform integrates into existing oncology workflows to help labs, clinicians, and researchers make informed decisions. GO's solutions aim to address challenges such as fragmented data, operational bottlenecks, and the pressure to scale precision care. Clinical trial enrollment rates for cancer patients are low, with fewer than 5% of adult cancer patients participating. Many trials, between 20% and 40%, fail to meet their enrollment targets, which can lead to premature termination of the study. This partnership between GenomOncology and WeTrials seeks to address this critical bottleneck in cancer research and treatment. AI's role in clinical trials is expanding, with applications ranging from optimizing patient recruitment to analyzing complex trial data. AI can accelerate trial timelines by automating tasks and quickly analyzing datasets, potentially reducing the duration of clinical trials from months to weeks. AI algorithms can also sift through data to identify suitable patients by analyzing medical records and genetic data. CNS tumors present a unique challenge, with clinical trial enrollment rates among adolescents and young adults (AYA) remaining poor. A study at Dana-Farber Cancer Institute found that only 15% of adult AYA patients with glioma enrolled in a clinical trial. This highlights the need for improved methods of matching CNS cancer patients with relevant clinical trials, which the GenomOncology and WeTrials partnership intends to facilitate.